PharmaMar S.A.. (5/17/17). "Press Release: PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries". Madrid.

	Region	Australia + New Zealand
	Organisation	PharmaMar S.A. (MSE: PHM)
	Group	PharmaMar (Group)
	Organisation 2	Specialised Therapeutics Australia Pty Ltd. (STA)
	Product	lurbinectedin (PM1183)
	Product 2	cancer drug
	Index term	Specialised Therapeutics Australia–PharmaMar: lurbinectedin, 201705– license to market lurbinectedin in AU + NZ + 12 Asian countries for STA
	Person	Fernandéz Sousa-Faro, José María (Zeltia 201411 Chairman of Zeltia + PharmaMar)
	Person 2	Montagner, Carlo (200801– CEO + Founder of STA before Alchemia + Abraxas Bioscience et al + Schering 200510)

PharmaMar (MSE:PHM) today announced an agreement with Singapore-based Specialised Therapeutics Asia Pte, Ltd (STA) to market the marine-based anti-tumour compound of the Company, lurbinectedin (PM1183) for the treatment of platinum-resistant ovarian cancer, small-cell lung cancer, BRCA 1/2 -associated metastatic breast cancer and other future oncology indications in Australia, New Zealand and in 12 Asian countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Timor-Leste, Thailand and Vietnam).

Under the terms of this license agreement and a related subscription agreement, Specialised Therapeutics Investments Pty LTD ATF The Specialised Therapeutics Unit Trust (STA Trust), an entity controlled by STA, has undertaken to subscribe 444,400 new common stock of PharmaMar, representing 0,2% of PharmaMar´s share capital, at a subscription price per share of €4.75, equal to a 30% premium over the volume weighted average market price of the shares of PharmaMar on the Spanish Stock Exchanges during the 20 trading days prior to the signing of the licence agreement. Therefore, the total subscription amount (nominal value and share premium) of the share capital increase of PharmaMar will be €2,110,900, corresponding €22,220 to nominal amount and €2,088,680 to share premium. STA Trust has agreed to a 2 years lock-up in respect of 50% of the shares and to a 4 years lock-up in respect of the remaining 50% of the shares.

In addition, PharmaMar will receive an upfront payment followed by remunerations upon achieving regulatory and sales milestones with lurbinectedin. PharmaMar will retain exclusive production rights and will supply the Finished Dosage Form to STA.

Lurbinectedin (PM1183), the third anti-tumour compound to be developed by PharmaMar from a marine organism, is currently undergoing development for the treatment of solid tumours. This promising agent is currently in final stage (Phase 3) trials as a potential new therapy for various solid tumours, including platinum-resistant ovarian cancer and small cell lung cancer. In addition, it is in Phase 2 trial for BRCA1 and BRCA2 associated metastatic breast cancer.

José María Fernández Sousa-Faro, Chairman of PharmaMar, commented, “we are about to address our second strategic alliance with STA for the commercialization of a marine-based cancer drug. Lurbinectedin has shown antitumoral activity in several solid tumors. We shall continue with the clinical development of the molecule and to advance in the upcoming regulatory steps to obtain its approval in the years to come”.

Carlo Montagner, CEO of Specialised Therapeutics Asia, said this new licensing deal cemented the company’s existing strong relationship with PharmaMar and demonstrated high confidence in the partner company’s development pipeline. “We have the highest regard for PharmaMar and are pleased to partner once again, pursuing development of this highly promising oncology compound”, he said. “We eagerly await data from these final stage studies and look forward to making new therapies like this available to patients throughout our regions who are affected by difficult to treat cancers”.

About PM1183 (lurbinectedin)

PM1183 is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction. The antitumor efficacy of lurbinectedin is being investigated in various types of solid tumors.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Austria, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Specialised Therapeutics Asia

Specialised Therapeutics Asia Pte Ltd (ST Asia) is an international biopharmaceutical company established to provide pioneering healthcare solutions to patients throughout South East Asia, as well as in Australia and New Zealand. The company is a close affiliate of Specialised Therapeutics Australia (STA), which also collaborates with leading global pharmaceutical and diagnostic companies to bring novel, innovative and life changing healthcare solutions to patients affected by a range of diseases. ST Asia is committed to making new and novel therapies available to patients around the world, with a broad therapeutic portfolio spanning oncology, hematology, urology and ophthalmology. Additional information can be found at www.STAbiopharma.com

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000

Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com

###

Record changed: 2023-06-05